
    
      This is a Phase 1b randomized, placebo-controlled, double-blind, crossover study to evaluate
      the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL747 in
      subjects with Alzheimer's disease (AD)
    
  